Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)

To join this study, you need to be at least 18 years old. You must have a diagnosis of chronic kidney disease with specific kidney function levels (eGFR between 20 and 90, and a high amount of protein in your urine). You should also be taking a specific type of blood pressure medication (like ACE inhibitors or ARBs) at a stable dose.

There are certain reasons why you might not be able to join. For example, if you have severe heart failure, have been hospitalised for heart problems recently, or have had organ transplants, you wouldn't be eligible. People with Type 1 diabetes, certain heart rhythm problems, or very high or low blood pressure are also not suitable for this study. If you're a woman, you'll need to have a negative pregnancy test and either be past childbearing age or using effective contraception.

If you decide to take part, you'll be randomly assigned to receive either the new combination treatment (Zibotentan/Dapagliflozin) or Dapagliflozin alone. Neither you nor your study doctor will know which treatment you are getting. You'll have regular visits to the clinic for health checks, blood and urine tests, and to make sure the medication is working well and you're not having any problems. The exact number of visits and the total duration of your participation will be explained in detail by the study team, but clinical trials usually involve ongoing assessments and sometimes follow-up after the main treatment period.